BIOMARK APPOINTS DR. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC

biomark appoints dr jean francois haince as strategic advisor to guide its expansion into quebec

Vancouver, British Columbia – (September 16th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team.

Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Haince into our advisory team. Jeff brings a pragmatic perspective to our bench strength along with a thorough understanding of engaging within the vibrant biotech ecosystem in Quebec and North America.  Jeff’s business and product development expertise with diverse medical, scientific, and business experience applied to strategic planning and innovation management in both academia and biotech industry are important for commercialization of BioMark’s disruptive cancer assays.  Jeff possesses a good understanding of the whole value chain and regulatory landscape in the pharmaceutical/healthcare industry and played a vital role in the commercialization of 2 early cancer detection molecular diagnostics.”

About Dr. Jean-Francois Haince

Dr. Haince holds a PhD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. He cumulates over 15 years of experience in cancer research and authored over 20 peer-reviewed scientific publications. During his term at DiagnoCure from 2007 to 2015, he has been responsible for the development of new molecular diagnostic tests from product design to clinical validation.  Dr. Haince currently manages a multidisciplinary team of experts at SOVAR, providing advice and project management support to development and deployment of technological innovations stemming from cutting-edge research. He also sits on the Research and Innovation Committee at the l’Institut National du Sport du Québec, advising the Institut’s scientific director on all issues related to its scientific and technical activities.

Press Release – BIOMARK APPOINTS Dr. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.